clinical trial · NCT05207670
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Genentech, Inc.·phase2·active not recruiting·n = 320
Non-Hodgkin LymphomaMosunetuzumab (Cohorts A-C)Mosunetuzumab (Cohorts D-E)Tocilizumab
brief summary
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \[NHL\]).
started
Feb 1, 2022
primary completion
Jul 31, 2028
completion
Jul 31, 2028
last updated
Mar 5, 2026
official title
An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol